CR9355A - Formulacion farmaceutica novedosa que contiene una biguanida y un derivado de tiazolidinadiona - Google Patents

Formulacion farmaceutica novedosa que contiene una biguanida y un derivado de tiazolidinadiona

Info

Publication number
CR9355A
CR9355A CR9355A CR9355A CR9355A CR 9355 A CR9355 A CR 9355A CR 9355 A CR9355 A CR 9355A CR 9355 A CR9355 A CR 9355A CR 9355 A CR9355 A CR 9355A
Authority
CR
Costa Rica
Prior art keywords
derivative
thiazolidinadiona
biguanida
pharmaceutical formulation
formulation containing
Prior art date
Application number
CR9355A
Other languages
English (en)
Inventor
Kazuhiro Okochi
Avinash Nangia
Unchalee Lodin
Jack R Cardinal
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9355(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR9355A publication Critical patent/CR9355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se expone y describe en la presente una forma de dosificacion farmaceutica que comprende un componente deliberacion controlada que comprende una droga antihiperglicemicaen combinacion con un segundo componente que comprende un derivado de tiazolodinadiona.
CR9355A 2005-03-30 2007-08-29 Formulacion farmaceutica novedosa que contiene una biguanida y un derivado de tiazolidinadiona CR9355A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/093,742 US9060941B2 (en) 2002-09-20 2005-03-30 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Publications (1)

Publication Number Publication Date
CR9355A true CR9355A (es) 2008-01-21

Family

ID=37073782

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9355A CR9355A (es) 2005-03-30 2007-08-29 Formulacion farmaceutica novedosa que contiene una biguanida y un derivado de tiazolidinadiona

Country Status (24)

Country Link
US (1) US9060941B2 (es)
EP (1) EP1863445B1 (es)
JP (2) JP5827781B2 (es)
KR (1) KR101401412B1 (es)
CN (1) CN101222912B (es)
AR (1) AR054238A1 (es)
AU (1) AU2006232993B2 (es)
BR (1) BRPI0609550A2 (es)
CA (1) CA2601501C (es)
CR (1) CR9355A (es)
EA (1) EA015244B1 (es)
ES (1) ES2573321T3 (es)
GE (1) GEP20104936B (es)
IL (1) IL186308A (es)
MA (1) MA29675B1 (es)
MX (1) MX2007011824A (es)
NO (1) NO20075427L (es)
NZ (1) NZ561124A (es)
PE (1) PE20061389A1 (es)
SG (1) SG160415A1 (es)
TW (1) TWI344375B (es)
UA (1) UA91852C2 (es)
WO (1) WO2006107528A1 (es)
ZA (1) ZA200707137B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
CN102036656A (zh) * 2008-03-21 2011-04-27 米兰制药有限公司 含有蜡的缓释制剂
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20120093878A1 (en) * 2010-07-30 2012-04-19 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a thiazolidinedione
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
CN101912375A (zh) * 2010-08-26 2010-12-15 冯岩 一种二甲双胍控释片
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
US20160113913A1 (en) * 2013-04-19 2016-04-28 Takeda Pharmaceutical Company Limited Controlled-release drug formulation
EP3025707A1 (en) * 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. A multilayer tablet comprising metformin and pioglitazone
EP3829546A1 (en) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4080472A (en) * 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4220648A (en) * 1979-01-22 1980-09-02 The Upjohn Company Antidiabetic 1,2-dihydro-2-oxo-6-neopentyl-nicotinic acids
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
CA1266827A (en) 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
FR2611500B1 (fr) 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
FI900470A7 (fi) 1989-01-31 1990-08-01 Ipa Int Pharma Agentur Gmbh Aktiiviaineita säädetysti vapauttava systeemi ja menetelmä sen valmistamiseksi
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH06510286A (ja) 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5294770A (en) * 1992-01-14 1994-03-15 Alza Corporation Laser tablet treatment system with dual access to tablet
US5376771A (en) * 1992-07-07 1994-12-27 Merck & Co., Inc. High speed process for preparing orifices in pharmaceutical dosage forms
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5917052A (en) 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5658474A (en) * 1994-12-16 1997-08-19 Alza Corporation Method and apparatus for forming dispenser delivery ports
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ES2224634T3 (es) 1998-04-29 2005-03-01 Sumitomo Pharmaceuticals Company, Limited Formulacion oral que comprende biguanida y un acido organico.
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
EP1093370B1 (en) * 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
HK1048956B (zh) 1999-05-27 2006-07-28 阿库斯菲尔公司 多孔药物基质及其制造方法
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
CA2394968A1 (en) * 1999-12-16 2001-06-21 Alza Corporation Dosage forms having a barrier layer to laser ablation
BR0007360A (pt) 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AU2000273085A1 (en) 2000-10-02 2002-04-15 Usv Limited Sustained release pharmaceutical compositions containing metformin and method ofits production
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
JPWO2002060448A1 (ja) 2001-01-30 2004-05-27 帝人株式会社 医薬組成物
JP4848558B2 (ja) 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
US6838093B2 (en) * 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
US6703045B2 (en) * 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
AU2002341959A1 (en) * 2001-10-04 2003-04-14 Case Western Reserve University Drug delivery devices and methods
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004067001A1 (ja) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
MXPA06012685A (es) 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
CN1327840C (zh) 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用

Also Published As

Publication number Publication date
IL186308A (en) 2014-05-28
ZA200707137B (en) 2014-07-30
SG160415A1 (en) 2010-04-29
EA015244B1 (ru) 2011-06-30
AU2006232993B2 (en) 2012-01-19
EA200702116A1 (ru) 2008-02-28
TW200718433A (en) 2007-05-16
MA29675B1 (fr) 2008-08-01
CA2601501A1 (en) 2006-10-12
KR20080005359A (ko) 2008-01-11
JP2013209426A (ja) 2013-10-10
IL186308A0 (en) 2011-08-01
EP1863445A1 (en) 2007-12-12
CN101222912B (zh) 2012-10-03
CN101222912A (zh) 2008-07-16
GEP20104936B (en) 2010-03-25
MX2007011824A (es) 2008-02-12
WO2006107528A1 (en) 2006-10-12
AR054238A1 (es) 2007-06-13
EP1863445A4 (en) 2012-08-01
US9060941B2 (en) 2015-06-23
JP2008534589A (ja) 2008-08-28
UA91852C2 (ru) 2010-09-10
NZ561124A (en) 2010-12-24
NO20075427L (no) 2007-10-25
TWI344375B (en) 2011-07-01
JP5827781B2 (ja) 2015-12-02
KR101401412B1 (ko) 2014-06-11
PE20061389A1 (es) 2007-01-21
EP1863445B1 (en) 2016-05-11
US20050226928A1 (en) 2005-10-13
AU2006232993A1 (en) 2006-10-12
ES2573321T3 (es) 2016-06-07
HK1114337A1 (en) 2008-10-31
CA2601501C (en) 2013-04-09
BRPI0609550A2 (pt) 2010-04-13

Similar Documents

Publication Publication Date Title
BRPI0414471A (pt) nova formulação farmacêutica contendo biguanida e um derivado de tiazolidinadiona
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2014001029A1 (es) Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012).
AR054060A1 (es) Forma de dosificacion farmaceutica unitaria
NO20075427L (no) Ny farmasoytisk formulering inneholdende et biguanid og et tiazolidindionderivat
DE602007012692D1 (de) Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
CL2009000541A1 (es) Uso de una enzima degradadora de matriz activable (amde) para la formulacion de un medicamento de administracion sub-epidermica; composicion farmacologica y su uso; combinacion que comprende a amde, un activador y un agente; recipiente para amde y para el activador; kit que comprende dicho recipiente
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
EP2037917A4 (en) Pharmaceutical composition comprising amlodipine and losartan
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
ECSP088889A (es) Forma nueva de administración de racecadotril
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
ECSP099483A (es) Combinación de un inhibidor de desacetilasa de histona y un antimetabolito
CL2007003855A1 (es) Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
WO2005117591A3 (en) Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
BRPI0514753A (pt) formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero
BRPI0518855A2 (pt) medicamento para aplicaÇço higiÊnica no ouvido
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SOLUBLE DEATH MEDICINE